# A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

> **NCT06612268** · PHASE3 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 408 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Etavopivat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06612268
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2027-08-27
- **Final completion:** 2029-03-12
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612268, "A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06612268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*